PIK3CA and neoplasm: Oral administration of ZN-c5 at 5 mg/kg and 10 mg/kg resulted in significant inhibition of tumor growth in MCF-7 orthotopic tumor xenograft models, and ZN-c5 combined with CDK4/6 or PI3K inhibitors enhanced antitumor activity.